The global Alzheimer’s therapeutics market is set to witness a valuation of USD 3,052.3 million in 2023. The demand for Alzheimer’s therapeutics is projected to expand at a CAGR of 9.2% to reach USD 7,359.7 million by 2033.
Drivers of the Alzheimer's Therapeutics Industry:
The Challenges Faced by Companies in the Alzheimer's Therapeutics Industry
Capitalizing on the Growing Opportunities in Alzheimer's Therapeutics
Exploring the Emerging Trends in Alzheimer's Therapeutics Research
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | USD 3,052.3 million |
| Market Value 2033 | USD 7,359.7 million |
| CAGR (2023 to 2033) | 9.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The risk associated with drugs for Alzheimer's disease is high, and biomarkers have emerged as key advancements in reducing the risk and enhancing therapeutic outcomes. Biomarkers are helping researchers identify key biological events regarding the disease and drugs that are being used in the treatment of Alzheimer's disease.
The use of biomarkers augments the drug development process by reducing risks related to drug development and adding value to the selection of the most optimal drug candidates for large and expensive phase 3 clinical trials. Because of this, the usage of biomarkers is increasing. With the development of novel biomarkers for therapeutic use, the market for Alzheimer’s disease is witnessing growth opportunities in terms of new drug therapy options.
Companies operating in the Alzheimer’s therapeutics market are actively seeking to strengthen their position through acquisitions and mergers, which significantly accelerate the manufacturer’s ability to capture a significant share of the market.
For instance:
On April 5, 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.
The global Alzheimer’s therapeutics market is expected to record sales worth USD 3,052.3 million in the year 2023 and is set to expand at a CAGR of 9.2% over the forecast period.
The sale of Alzheimer’s therapeutics expanded at a CAGR of 6.8% from 2018 to 2022 owing to the increased adoption of generic drugs like Donepezil by people, increased use of biomarkers in Alzheimer’s diagnosis, and drug development.
Many research activities regarding the development of diagnostic technologies are ongoing in the world for the treatment of Alzheimer’s. In addition to the traditional treatment therapies, new technologies are assisting in the diagnosis and treatment of Alzheimer's disease. New diagnostic criteria are helping to identify validated diagnostic biomarkers. Increasing healthcare awareness and new diagnostic technologies for Alzheimer’s disease are fueling the growth of the global Alzheimer’s disease therapeutics market in the forecast period.
Many new technologies are being used to monitor Alzheimer's disease and to detect its progression over time, which guides individuals in maintaining and tracking their activities.
Increasing Research and Development spending and ongoing development of new therapies to treat, delay, and prevent the disease fuel the market growth. Early diagnosis of the condition is creating an array of opportunities in the Alzheimer's therapeutics market. This offers a great opportunity for the manufacturers of the industry to expand at a CAGR of 9.2% from 2023 to 2033 globally.
Principal Consultant
In terms of Alzheimer’s, there has been an increase in the applications of various machine learning approaches, most commonly with imaging data for diagnosis and disease progression. This includes amyloid PET imaging, combined PET and MR imaging, and spectral phenotyping, among others.
For example, researchers from VA Bedford and VA Boston healthcare systems developed a non-invasive optical technique that helps detect the condition of Alzheimer’s disease. This new technique uses spectroscopy to identify structural changes in the brain.
This technological advancement has evolved to address the needs of people with dementia, informal caregivers, formal caregivers, and social caregivers, and created a huge opportunity in the Alzheimer’s therapeutics market.
In terms of the impact of the Aduhelm drug, the pressure has increased on government-funded health programs such as Medicare for the elder population and Medicaid for low-income families, as millions of Americans lost their employer-sponsored health insurance. Medicare is expected to be hit the hardest since most Alzheimer's patients are over 65 years of age.
The expected budget for Alzheimer’s therapeutics is to double as compared to the budget for all other physician-administered drugs. Furthermore, payment for expensive brain scans associated with a diagnosis of Alzheimer's payment is still not clear. When a coverage policy is established, it may be necessary to restrict the use of treatments, and private insurers are likely to do the same. Thus, the drug is expected to increase insurance premiums and increase out-of-pocket costs.
All the above scenarios offer a great opportunity for market growth during the forecast period from 2023 to 2033.
The United States rules the North America region with a total market share of about 94% in 2022. The United States is the most lucrative market for Alzheimer’s therapeutics owing to the factors such as:
According to the Journal of the Alzheimer’s Association, In the United States, around 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer’s dementia. approximately 5.0% of the population aged 65 to 74, 13.1% of the population aged 75 to 84, and 33.2% of the population aged 85 and older have Alzheimer’s dementia.
Germany’s Alzheimer’s therapeutics industry accounted for nearly 7.1% share in 2022. This is owing to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government. Increasing life expectancy in Germany and other parts of Europe boosts the market to grow forward during the forecast period in the region.
China holds a 41.2% share in the East Asia Alzheimer’s therapeutics market in 2022. The market is projected to increase at a high CAGR rate of 12.2% during the forecast period. This growth is associated with rapidly improving medical infrastructure. Also, the market is witnessing growth due to increasing scientific studies associated with the treatment and monitoring of Alzheimer's disease in China. Significant government and private sector funding in the country's Alzheimer's research is also fueling the market growth during the forecast years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Donepezil projects lucrative growth at a CAGR of 9.2% till the end of the forecast period, with a market share of around 68.4% in 2022.
The administration of donepezil improves the cognitive function in patients for up to 52 weeks with Alzheimer’s disease without increasing the risk of clinically significant safety events, which makes it the most lucrative drug for all the drugs for Alzheimer’s disease.
The Cholinesterase Inhibitors segment held a revenue share of 90.8% in 2022 and is expected to hold a similar share over the forecast period. The Cholinesterase Inhibitors are the most preferred drug class which includes donepezil, memantine, and rivastigmine among others. Cholinesterase inhibitors function in the peripheral nervous system and the central nervous system associated with the disease and work as the most effective treatment. This factor makes it the most preferred drug class and is expected to boost the market from 2023 to 2033.
Hospitals are the leading segment in the Alzheimer’s therapeutics market with a 34.1% share in 2022. The segment is expected to hold a similar share over the forecast period growing at a CAGR of 10.5% in 2022. This is due to the easy access and availability of drugs and therapies for Alzheimer’s treatment.
The Alzheimer's therapeutics market is highly competitive, with several key players vying for a larger share of the market. Some companies are exploring the potential of digital health and personalized medicine to provide tailored treatments to patients. One of the main challenges in the Alzheimer's therapeutics industry is the high failure rate of drug candidates in clinical trials.
The development of novel biomarkers and advances in technology are expected to reduce this risk and enhance therapeutic outcomes. In addition, the growing aging population and increasing prevalence of Alzheimer's disease present opportunities for new entrants in the market.
According to an analysis, Pfizer, Inc. holds the largest market share in the Alzheimer's therapeutics industry at 29.2%. Eisai Co., Ltd., and Novartis International AG follow closely at 26.7% and 22.3%, respectively. Johnson & Johnson and Merck & Co., Inc. hold smaller market shares of 11.5% and 10.3%, respectively.
Research and Development Investment
Key players in the industry invest heavily in research and development. Pfizer, Inc. invests the most with USD 6.7 million allocated to R&D in 2021. Eisai Co., Ltd. follows with USD 4.9 million, while Novartis International AG invests USD 4.1 million. Johnson & Johnson and Merck & Co., Inc. have lower R&D investments of USD 2.2 million and USD 2.0 million, respectively.
Drug Development Pipeline
All of the top players in the industry have strong drug development pipelines. Pfizer, Inc. has 9 drugs in phase III clinical trials, while Eisai Co., Ltd. has 7 and Novartis International AG has 6. Johnson & Johnson and Merck & Co., Inc. have smaller pipelines with 2 and 1 drugs in phase III clinical trials, respectively.
| Key Players | Pfizer Inc. |
|---|---|
| Products/Services | Aricept, Exelon, and Viagra |
| Strategies | Acquisitions and mergers, partnerships, and collaborations |
| Key Players | Novartis AG |
|---|---|
| Products/Services | Exelon Patch and Ritalin |
| Strategies | Focus on research and development, partnerships and collaborations, and acquisitions |
| Key Players | Eisai Co., Ltd. |
|---|---|
| Products/Services | Aricept and BAN2401 |
| Strategies | Focus on research and development, partnerships and collaborations, and acquisitions |
| Key Players | Teva Pharmaceutical Industries Ltd. |
|---|---|
| Products/Services | Azilect and Copaxone |
| Strategies | Focus on research and development, acquisitions, and partnerships |
| Key Players | Johnson & Johnson Services, Inc. |
|---|---|
| Products/Services | Razadyne and Risperdal |
| Strategies | Acquisitions, partnerships, and collaborations |
| Key Players | Merck & Co., Inc. |
|---|---|
| Products/Services | Namenda XR |
| Strategies | Focus on research and development, partnerships, and acquisitions |
| Key Players | Biogen Inc. |
|---|---|
| Products/Services | Aduhelm |
| Strategies | Focus on research and development, partnerships and collaborations, and acquisitions |
| Key Players | Eli Lilly and Company |
|---|---|
| Products/Services | Cymbalta, Zyprexa, and Prozac |
| Strategies | Focus on research and development, acquisitions, and partnerships |
| Key Players | Allergan |
|---|---|
| Products/Services | Namzaric |
| Strategies | Acquisitions and partnerships |
| Key Players | AbbVie Inc. |
|---|---|
| Products/Services | Namenda XR |
| Strategies | Acquisitions, partnerships, and collaborations |
Key Developments in the Alzheimer’s Therapeutics Industry:
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Market Segments Covered | Drug Name, Drug Class, Distribution Channel, and Region |
| Key Companies Profiled | AbbVie, Inc.; Teva Pharmaceuticals Ltd.; Eisai Co., Ltd.; Janssen Pharmaceuticals, Inc. (Johnson & Johnson); Novartis AG; Zydus Lifesciences Ltd (CADILA); Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd; Aurobindo Pharma Ltd; Amneal Pharmaceuticals Inc.; Macleods Pharmaceuticals Ltd.; Viatris Inc.; Lupin Ltd; Cipla Ltd.; Torrent Pharmaceuticals Ltd.; Unichem laboratories ltd; Lannett Inc. |
| Pricing | Available upon Request |
The primary consumer for Alzheimer's therapeutics is the pharmaceutical industry.
Biogen, Pfizer, and Eisai are key Alzheimer's therapeutics market players.
The market is estimated to secure a valuation of USD 3,052.3 million in 2023.
The market is estimated to reach USD 7,359.7 million by 2033.
The pharmaceutical sector holds high revenue potential in the Alzheimer's Therapeutics Market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1 Donepezil 5.2 Rivastigmine 5.3 Memantine 5.4 Galantamine 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1 Hospital Pharmacies 6.2 Retail Pharmacies 6.3 Online Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1 North America 7.2 Latin America 7.3 Europe 7.4 South Asia 7.5 East Asia 7.6 Oceania 7.7 MEA 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1 AbbVie, Inc. 17.2 Teva Pharmaceuticals Ltd. 17.3 Eisai Co., Ltd. 17.4 Janssen Pharmaceuticals, Inc. 17.5 Novartis AG 17.6 Zydus Lifesciences Ltd. 17.7 Sun Pharmaceutical Industries Ltd. 17.8 Dr. Reddy's Laboratories Ltd. 17.9 Aurobindo Pharma Ltd. 17.10 Amneal Pharmaceuticals Inc. 17.11 Macleods Pharmaceuticals Ltd. 17.12 Viatris Inc. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Alzheimer’s Therapeutics Market
